Vifor Pharma AG (0RPD.L)
LSE - LSE Delayed price. Currency in CHF
Add to watchlist
132.35+10.00 (+8.17%)
At close: 6:05PM GMT
| Previous close | 122.35 |
| Open | 123.40 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 123.10 - 140.95 |
| 52-week range | 123.10 - 140.95 |
| Volume | 41,121 |
| Avg. volume | N/A |
| Market cap | 8.573B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 53.15 |
| EPS (TTM) | 2.49 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency
Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress.
- Business Wire
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
- Business Wire
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
© 2020 Verizon Media. All rights reserved.
